Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
20 Julio 2023 - 5:00AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the
Company) today announced that it will release financial and
operational results for the second quarter of 2023, on Thursday,
August 3, 2023, before markets open. Aurinia’s management team will
host a conference call/webcast at 8:30 am ET that day to review
these results and provide a general business update. Interested
participants can dial (888) 645-4404 / (862) 298-0702 (Toll-free
U.S. & Canada). The audio webcast can also be accessed under
"News/Events” through the “Investors” section of the Aurinia
corporate website at www.auriniapharma.com. A replay of the webcast
will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations with a high unmet medical need that are impacted by
autoimmune, kidney and rare diseases. In January 2021, the Company
introduced LUPKYNIS® (voclosporin), the first FDA-approved oral
therapy for the treatment of adult patients with active lupus
nephritis (LN). The Company’s head office is in Edmonton, Alberta,
its U.S. commercial hub is in Rockville, Maryland, and the Company
focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230720800635/en/
Investors/Media: ir@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfica de Acción Histórica
De May 2023 a May 2024